Proteomics in Uveal Melanoma
Analysis of proteins in blood and ocular fluids may provide new opportunities for diagnosis, prognostication, and therapeutic discovery.
-
By
-
Arun D. Singh, MD
-
Kevin Allan, MD, PhD
-
September 1, 2026
-
Clinical Scorecard: Proteomics in Uveal Melanoma
At a Glance
| Category | Detail |
|---|
| Condition | Uveal Melanoma |
| Key Mechanisms | Proteomics for tumor characterization, prognostication, and metastasis detection. |
| Target Population | Patients with uveal melanoma. |
| Care Setting | Ophthalmic clinical practice. |
Key Highlights
- Nearly 40% of uveal melanoma patients develop metastatic disease over the long term.
- Proteomics can identify proteins that govern cellular behavior, aiding in diagnosis and treatment monitoring.
- Aqueous humor sampling offers a less invasive method for obtaining proteomic data.
- Targeted serum proteomics demonstrated better sensitivity than conventional liver function tests.
- Proteomic signatures can provide insights distinct from tumor transcriptomes.
Guideline-Based Recommendations
Diagnosis
- Utilize aqueous humor proteomics for diagnostic potential in uveal melanoma.
Management
- Consider proteomic profiling for monitoring treatment response and tumor burden.
Monitoring & Follow-up
- Aqueous humor proteomics allows for longitudinal monitoring of tumor burden.
Risks
- Invasive biopsy carries risks such as vitreous hemorrhage and retinal detachment.
Patient & Prescribing Data
Patients diagnosed with uveal melanoma.
Proteomic markers may assist in identifying therapeutic targets and monitoring treatment response.
Clinical Best Practices
- Incorporate proteomic analysis alongside traditional gene expression profiling.
- Utilize minimally invasive sampling techniques for better patient safety and data accuracy.
Related Resources & Content
